Trevi Therapeutics, Inc. 8-K

What Happened

• Trevi Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026. The company furnished a press release with the results as Exhibit 99.1 to its Form 8-K filed on May 5, 2026. The filing was signed by David C. Hastings, Chief Financial Officer.

Key Details

• Item reported: 2.02 — Results of Operations and Financial Condition (quarter ended March 31, 2026).
• Press release: Exhibit 99.1 was furnished (not filed) with the Form 8-K and was issued May 5, 2026.
• Interactive data: Inline XBRL cover page (Exhibit 104) was included in the filing.
• Form 8-K signed by: David C. Hastings, Chief Financial Officer, dated May 5, 2026.

Why It Matters

• An 8-K announcing quarterly results is material information that can affect investor decisions and the stock price. Investors should review the furnished press release (Exhibit 99.1) or the company’s investor relations page for specific figures—revenue, net income/loss, cash position, and any commentary on outlook or guidance—before making investment choices.